Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms

Takahiro Einama, Hirofumi Kamachi, Hiroshi Nishihara, Shigenori Homma, Hiromi Kanno, Marin Ishikawa, Futoshi Kawamata, Yuji Konishi, Masanori Sato, Munenori Tahara, Kuniaki Okada, Shunji Muraoka, Toshiya Kamiyama, Akinobu Taketomi, Yoshihiro Matsun, Hiroyuki Furukawa, Satoru Todo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low-high (L-H) grade dysplasias. The tumors were classified as mesothelin-positive or -negative and in the mesothelin-positive cases, the localization of mesothelin was evaluated as luminal membrane- or cytoplasmic-positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8%), including 46.2% (12 out of 26) of the L-H dysplasia and 81.8% (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27%), including 15.4% (4/26) of the L-H dysplasia samples and 54.5% (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post-operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.

Original languageEnglish
Pages (from-to)1583-1589
Number of pages7
JournalOncology Letters
Volume9
Issue number4
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Membranes
Neoplasms
Carcinoma
mesothelin
Adenoma
Stomach Neoplasms
Decision Making
Cell Membrane
Recurrence

Keywords

  • Intraductal papillary mucinous neoplasms
  • Luminal membrane expression
  • Mesothelin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms. / Einama, Takahiro; Kamachi, Hirofumi; Nishihara, Hiroshi; Homma, Shigenori; Kanno, Hiromi; Ishikawa, Marin; Kawamata, Futoshi; Konishi, Yuji; Sato, Masanori; Tahara, Munenori; Okada, Kuniaki; Muraoka, Shunji; Kamiyama, Toshiya; Taketomi, Akinobu; Matsun, Yoshihiro; Furukawa, Hiroyuki; Todo, Satoru.

In: Oncology Letters, Vol. 9, No. 4, 01.01.2015, p. 1583-1589.

Research output: Contribution to journalArticle

Einama, T, Kamachi, H, Nishihara, H, Homma, S, Kanno, H, Ishikawa, M, Kawamata, F, Konishi, Y, Sato, M, Tahara, M, Okada, K, Muraoka, S, Kamiyama, T, Taketomi, A, Matsun, Y, Furukawa, H & Todo, S 2015, 'Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms', Oncology Letters, vol. 9, no. 4, pp. 1583-1589. https://doi.org/10.3892/ol.2015.2969
Einama, Takahiro ; Kamachi, Hirofumi ; Nishihara, Hiroshi ; Homma, Shigenori ; Kanno, Hiromi ; Ishikawa, Marin ; Kawamata, Futoshi ; Konishi, Yuji ; Sato, Masanori ; Tahara, Munenori ; Okada, Kuniaki ; Muraoka, Shunji ; Kamiyama, Toshiya ; Taketomi, Akinobu ; Matsun, Yoshihiro ; Furukawa, Hiroyuki ; Todo, Satoru. / Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms. In: Oncology Letters. 2015 ; Vol. 9, No. 4. pp. 1583-1589.
@article{d8a57ab29a214ab0acb7473c8b6761c7,
title = "Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms",
abstract = "The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low-high (L-H) grade dysplasias. The tumors were classified as mesothelin-positive or -negative and in the mesothelin-positive cases, the localization of mesothelin was evaluated as luminal membrane- or cytoplasmic-positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8{\%}), including 46.2{\%} (12 out of 26) of the L-H dysplasia and 81.8{\%} (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27{\%}), including 15.4{\%} (4/26) of the L-H dysplasia samples and 54.5{\%} (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post-operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.",
keywords = "Intraductal papillary mucinous neoplasms, Luminal membrane expression, Mesothelin",
author = "Takahiro Einama and Hirofumi Kamachi and Hiroshi Nishihara and Shigenori Homma and Hiromi Kanno and Marin Ishikawa and Futoshi Kawamata and Yuji Konishi and Masanori Sato and Munenori Tahara and Kuniaki Okada and Shunji Muraoka and Toshiya Kamiyama and Akinobu Taketomi and Yoshihiro Matsun and Hiroyuki Furukawa and Satoru Todo",
year = "2015",
month = "1",
day = "1",
doi = "10.3892/ol.2015.2969",
language = "English",
volume = "9",
pages = "1583--1589",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms

AU - Einama, Takahiro

AU - Kamachi, Hirofumi

AU - Nishihara, Hiroshi

AU - Homma, Shigenori

AU - Kanno, Hiromi

AU - Ishikawa, Marin

AU - Kawamata, Futoshi

AU - Konishi, Yuji

AU - Sato, Masanori

AU - Tahara, Munenori

AU - Okada, Kuniaki

AU - Muraoka, Shunji

AU - Kamiyama, Toshiya

AU - Taketomi, Akinobu

AU - Matsun, Yoshihiro

AU - Furukawa, Hiroyuki

AU - Todo, Satoru

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low-high (L-H) grade dysplasias. The tumors were classified as mesothelin-positive or -negative and in the mesothelin-positive cases, the localization of mesothelin was evaluated as luminal membrane- or cytoplasmic-positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8%), including 46.2% (12 out of 26) of the L-H dysplasia and 81.8% (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27%), including 15.4% (4/26) of the L-H dysplasia samples and 54.5% (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post-operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.

AB - The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low-high (L-H) grade dysplasias. The tumors were classified as mesothelin-positive or -negative and in the mesothelin-positive cases, the localization of mesothelin was evaluated as luminal membrane- or cytoplasmic-positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8%), including 46.2% (12 out of 26) of the L-H dysplasia and 81.8% (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27%), including 15.4% (4/26) of the L-H dysplasia samples and 54.5% (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post-operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.

KW - Intraductal papillary mucinous neoplasms

KW - Luminal membrane expression

KW - Mesothelin

UR - http://www.scopus.com/inward/record.url?scp=84923169592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923169592&partnerID=8YFLogxK

U2 - 10.3892/ol.2015.2969

DO - 10.3892/ol.2015.2969

M3 - Article

VL - 9

SP - 1583

EP - 1589

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -